Zhonghua nei ke za zhi · 2009
[Autologous bone marrow-derived mesenchymal stem cells and peripheral blood stem cells cotransplantation in treatment of hematological malignant diseases].
Клиническое исследованиеАннотация на английскомСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Tao, Bai Hai, Wang Cun-bang, Zhang Qian, Tantai Lin-fang, Wang Xiao-jing, Ou Jian-feng, Zhao Qiang
Аннотация
OBJECTIVE: To explore the feasibility and safety of cotransplantation of autologous bone marrow-derived mesenchymal stem cells (MSCs) and peripheral blood stem cells in hematological malignant diseases and to observe its effect on hematopoietic reconstruction after cotransplantation.
METHODS: Adult human MSCs were isolated from the healthy bone marrow of the patient himself with Percoll (1.073 g/ml) and cultured in Dulbecco's modified Eagle's medium with low glucose containing 10% AB type human serum. After conditioning regimen of high-dose chemotherapy and radiotherapy, cotransplantation of autologous bone marrow-derived MSCs and peripheral blood stem cells was done in five patients with hematological malignant diseases.
RESULTS: The process of the infusion was safe and there were no adverse reactions or other toxicities related to the infusion of MSCs. The median time to achieve neutrophil counts greater than 0.5x10(9)/L was 9.4 days (ranging from 8 to 11 days) after cotransplantation and platelet counts greater than 20x10(9)/L 12.2 days (ranging from 10 to 14 days).
CONCLUSION: Cotransplantation of autologous bone marrow-derived MSCs and peripheral blood stem cells in hematological malignant diseases is feasible and safe. The rapid hematopoietic reconstruction after cotransplantation shows that MSCs have an effect on hematopoiesis, but the mechanism is still to be investigated.
METHODS: Adult human MSCs were isolated from the healthy bone marrow of the patient himself with Percoll (1.073 g/ml) and cultured in Dulbecco's modified Eagle's medium with low glucose containing 10% AB type human serum. After conditioning regimen of high-dose chemotherapy and radiotherapy, cotransplantation of autologous bone marrow-derived MSCs and peripheral blood stem cells was done in five patients with hematological malignant diseases.
RESULTS: The process of the infusion was safe and there were no adverse reactions or other toxicities related to the infusion of MSCs. The median time to achieve neutrophil counts greater than 0.5x10(9)/L was 9.4 days (ranging from 8 to 11 days) after cotransplantation and platelet counts greater than 20x10(9)/L 12.2 days (ranging from 10 to 14 days).
CONCLUSION: Cotransplantation of autologous bone marrow-derived MSCs and peripheral blood stem cells in hematological malignant diseases is feasible and safe. The rapid hematopoietic reconstruction after cotransplantation shows that MSCs have an effect on hematopoiesis, but the mechanism is still to be investigated.